Skip to main content

Ago2 Immunoprecipitation for RISC-siRNA Quantitation

 Ago2 (Argonaute 2) immunoprecipitation (IP) is a technique used to isolate RNA-induced silencing complexes (RISC) from cell lysates. This method allows for the specific enrichment of active RISC complexes bound to small interfering RNA (siRNA) or microRNA (miRNA) within cells. By isolating these complexes, researchers can then quantify the siRNA associated with Ago2, which is an essential step in determining the efficacy of RISC loading and siRNA activity.

Here’s a detailed overview of how Ago2 immunoprecipitation is performed for RISC-siRNA quantitation:

Steps in Ago2 Immunoprecipitation for RISC-siRNA Quantitation

  1. Cell Lysis and Preparation of Lysate:

    • Sample Preparation: Collect cells that have been treated with siRNA, then wash them with cold phosphate-buffered saline (PBS) to remove extracellular contaminants.
    • Lysis: Lyse the cells in a gentle, RNA-preserving lysis buffer that typically includes detergents (e.g., NP-40 or Triton X-100), protease inhibitors, and RNase inhibitors to protect both protein and RNA from degradation.
    • Centrifugation: Centrifuge the lysate to remove cell debris and keep the supernatant containing Ago2-RISC complexes.

  2. Immunoprecipitation with Ago2 Antibody:

    • Antibody Incubation: Add an anti-Ago2 antibody to the lysate and incubate under gentle rotation at 4°C for a few hours to overnight, allowing the antibody to bind to Ago2-RISC complexes.
    • Beads Addition: Use protein A/G magnetic beads or agarose beads pre-blocked with BSA or another protein to minimize non-specific binding. Add the beads to the lysate, which allows the Ago2-antibody complex to bind to the beads.
    • Washing Steps: Perform multiple washes with a low-salt buffer to remove non-specific binding while retaining Ago2-bound siRNA on the beads. Washing steps should be thorough but gentle to avoid disrupting the RISC complexes.

  3. Elution of RISC Complexes:

    • Elution from Beads: Elute the Ago2-RISC complexes from the beads. This can be achieved either by using a mild elution buffer or, in some cases, by denaturing the sample if downstream RNA quantification is not affected by protein denaturation.
    • RNA Extraction (Optional): If necessary, extract the RNA from the immunoprecipitated sample to obtain a purified siRNA fraction, often using a commercial RNA extraction kit.

  4. Quantification of siRNA:

    • qPCR or RT-qPCR: To quantify siRNA, reverse transcribe the isolated siRNA (if necessary) and perform quantitative PCR (qPCR) or reverse transcription-qPCR (RT-qPCR) to detect and quantify the siRNA specifically associated with Ago2.
    • Normalization: Normalize the siRNA levels against housekeeping controls or total input to ensure accurate quantitation of RISC-loaded siRNA. Alternatively, standard curves can be used for absolute quantification.
    • miRNA as Endogenous Controls: If applicable, endogenous miRNAs associated with Ago2 can serve as controls to assess the efficiency of the immunoprecipitation.

Considerations for Accurate RISC-siRNA Quantification

  • Antibody Specificity: Use a high-specificity anti-Ago2 antibody to minimize cross-reactivity with other proteins, as this improves the accuracy of siRNA quantitation.
  • RNase-Free Conditions: As siRNA is highly susceptible to degradation, use RNase-free reagents, pipette tips, and tubes throughout the experiment.
  • Avoiding Over-Washing: Excessive washing can lead to loss of weakly bound siRNA from Ago2, potentially underestimating siRNA levels.
  • Standard Curve for siRNA Quantification: Using a standard curve with known concentrations of the siRNA allows absolute quantification, which is useful when comparing RISC loading across different samples.

Advantages of Ago2 Immunoprecipitation for RISC-siRNA Quantification

  1. Specificity for Active RISC: This method specifically isolates siRNA bound to Ago2, allowing accurate assessment of active RISC-bound siRNA, which directly correlates with gene silencing efficacy.
  2. Insight into siRNA Efficiency: Quantifying Ago2-bound siRNA can provide insights into the efficiency of RISC loading, helping to optimize siRNA design and dosage for therapeutic applications.
  3. Application to miRNA Research: The method can also be applied to study endogenous miRNAs bound to Ago2, providing insights into both endogenous and exogenous RNA silencing mechanisms.

Limitations and Challenges

  1. Requirement for High-Quality Antibodies: The success of this assay heavily depends on the availability of high-quality, highly specific anti-Ago2 antibodies.
  2. Potential Loss of Weakly Bound siRNA: Weakly bound siRNA might dissociate during washing, potentially underestimating the true RISC-associated siRNA levels.
  3. High Sensitivity of siRNA to Degradation: Since siRNA is easily degraded, rigorous RNase-free techniques are essential, adding complexity to the workflow.

Summary

Ago2 immunoprecipitation is a valuable method for quantifying siRNA within active RISC complexes, allowing researchers to measure the extent of siRNA incorporation into RISC and evaluate its gene-silencing potential. By providing specific enrichment of Ago2-bound siRNA, this technique offers detailed insights into siRNA activity and efficacy, crucial for optimizing siRNA-based therapeutics and understanding RNA interference mechanisms.

Popular posts from this blog

Human Genome Editing: FDA Draft Guidance Summary

Consideration for Developing Gene Editing Product  1. Genome Editing Methods: Genome editing can be achieved through nuclease-dependent or nuclease-independent methods. Nuclease-dependent methods involve introducing site-specific breaks in DNA using technologies like zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), modified-homing endonucleases, and CRISPR-associated (Cas) nucleases. These breaks can lead to modification of the DNA sequence at the cleavage site. Nuclease-independent methods can change DNA sequences without cleaving the DNA and include techniques like base editing and synthetic triplex-forming peptide nucleic acids. The choice of GE technology should consider factors such as the mechanism of action, the ability to target specific DNA sequences, and the potential to optimize components for efficiency, specificity, or stability. 2. Type and Degree of Genomic Modification: Different GE approaches rely on DNA repair pathways such a...
Read more

Stem loop RT-PCR for Detection of siRNA in Animal Tissues

Step Loop RT-PCR for Detection of Small Interfering RNA (siRNA) The recent publications described a novel used the novel method for the detection of siRNAs using a TaqMan®-based approach. This approach utilizes similar strategy that has been used for microRNA detection. The approach is illustrated in below.  In brief, the RT step occurs in the presence of a stem-loop RT primer that is complementary to the last 6–10 bases of the 3′ end of the antisense strand of the target siRNA. The stem-loop primer contains an additional universal sequence at the 5′ end that facilitates a TaqMan-based detection strategy in the subsequent qPCR step. As in the case of microRNA, the forward primer for qPCR is sequence-specific for the target siRNA. For sequence compositions that yield a low predicted melting temperature (Tm), the forward primer is designed as a tailed primer to help increase Tm. Stem Loop PCR for SiRNA Detection Step 1: Preparation of liver and plasma samples for the quanti...
Read more

ICH Q8 (R2) Pharmaceutical development (CHMP/ICH/167068/04)

 ICH Q8 (R2) is a guideline titled "Pharmaceutical Development" (CHMP/ICH/167068/04). This guideline is part of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) and provides recommendations for the pharmaceutical development of medicinal products. It offers a structured approach to the development of pharmaceutical products to ensure their quality, safety, and efficacy. Here's an elaboration of ICH Q8 (R2): 1. Purpose of ICH Q8 (R2): The primary purpose of ICH Q8 (R2) is to provide a systematic and science-based approach to pharmaceutical development. The guideline aims to facilitate the design and development of high-quality pharmaceutical products that meet the needs of patients and regulatory authorities. 2. Scope: ICH Q8 (R2) applies to the development of all types of pharmaceutical products, including small molecules, biotechnological products, and other complex medicinal products. 3. Pharmaceutical Develop...
Read more

Cell-Mediated Immunity in AAV Gene Therapy

Cell-mediated immunity (CMI) plays a significant role in the effectiveness and safety of AAV (Adeno-Associated Virus) gene therapy. Understanding the impact of CMI is crucial for optimizing therapeutic outcomes and managing potential adverse effects. Here’s a detailed overview of the impact of CMI on AAV gene therapy: 1. Mechanisms of Cell-Mediated Immunity in AAV Gene Therapy T-Cell Activation : After administration of an AAV vector, T cells can recognize the AAV capsid proteins or the transgene product as foreign antigens, leading to their activation. This can involve both CD4+ helper T cells and CD8+ cytotoxic T cells. Cytokine Production : Activated T cells produce cytokines (e.g., IFN-γ, TNF-α) that can enhance the immune response. These cytokines can influence the activation and proliferation of other immune cells, including B cells and macrophages. 2. Impact on Efficacy of AAV Gene Therapy Enhanced Antigen Presentation : CMI can improve the presentation of transgene-derived anti...
Read more

Preclinical Studies for AAV Gene Therapy

 Preclinical studies for AAV gene therapy are crucial to assess the safety, efficacy, biodistribution, and immunogenicity of the therapy before progressing to human trials. These studies help in understanding the potential risks and therapeutic effects in animal models, which is essential for regulatory approval to proceed to first-in-human studies. Here’s a breakdown of key preclinical study types and their objectives: 1. Efficacy Studies Objective : Determine whether the gene therapy delivers a therapeutic benefit in relevant disease models, such as improvement in phenotypic markers or functional outcomes. Study Design : Use disease-specific animal models that reflect the condition the therapy intends to treat (e.g., knockout models for genetic disorders). Evaluate therapeutic endpoints, such as protein expression, functional assays, or phenotypic changes. Example : For a neurological condition, measure motor function or cognitive outcomes in treated versus control groups. 2. Bio...
Read more